Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd63-KH
- Development stage
- Phase 2
- Lead developer
- University of York
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAd63-KH is a therapeutic vaccine developed for the treatment of leishmaniasis, specifically post-kala-azar dermal leishmaniasis (PKDL), visceral leishmaniasis (VL), and cutaneous leishmaniasis (CL). It uses a non-replicating simian adenoviral vector to introduce genes that code for Leishmania proteins into the human body. The design of ChAd63-KH is similar to the Oxford/AstraZeneca COVID-19 vaccine, using a replication-defective simian adenoviral vector. It expresses KH, a self-cleaving polyprotein comprising L. donovani KMP-11 and HASPB proteins. The vaccine is designed to induce immune responses against Leishmania parasites in patients with existing disease, rather than prevent infection.
- Other names
- KH vaccineLeishmania vaccine ChAd63-KH
Beyond the preview
Go deeper on ChAd63-KH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd63-KH.